DOCSLIB.ORG

CSF3R T618I Is a Highly Prevalent and Specific Mutation in Chronic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CSF3R T618I Is a Highly Prevalent and Specific Mutation in Chronic Leukemia (2013) 27, 1870–1873 & 2013 Macmillan Publishers Limited All rights reserved 0887-6924/13 www.nature.com/leu ORIGINAL ARTICLE CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia A Pardanani1, TL Lasho1, RR Laborde1, M Elliott1, CA Hanson2, RA Knudson3, RP Ketterling3, JE Maxson4,5, JW Tyner5,6 and A Tefferi1 Truncation mutations of the receptor cytoplasmic domain for colony-stimulating factor 3 (CSF3R) are frequently seen in severe congenital neutropenia, whereas activating missense mutations affecting the extracellular domain (exon 14) have been described in hereditary neutrophilia and chronic neutrophilic leukemia (CNL). In order to clarify mutational frequency, specificity and phenotypic associations, we sequenced CSF3R exons 14–17 in 54 clinically suspected cases of CNL (n ¼ 35) or atypical chronic myeloid leukemia (aCML; n ¼ 19). Central review of these cases confirmed WHO-defined CNL in 12 patients, monoclonal gammopathy (MG)-associated CNL in 5 and WHO-defined aCML in 9. A total of 14 CSF3R mutations were detected in 13 patients, including 10 with CSF3RT618I (exon 14 mutation, sometimes annotated as CSF3R T595I). CSF3RT618I occurred exclusively in WHO- defined CNL with a mutational frequency of 83% (10 of 12 cases). CSF3R mutations were not seen in aCML or MG-associated CNL. CSF3RT618I was also absent among 170 patients with primary myelofibrosis (PMF; n ¼ 76) or chronic myelomonocytic leukemia (CMML; n ¼ 94). SETBP1 mutational frequencies in WHO-defined CNL, aCML, CMML and PMF were 33, 0, 7 and 3%, respectively. Four CSF3RT618I-mutated cases co-expressed SETBP1 mutations. We conclude that CSF3RT618I is a highly sensitive and specific molecular marker for CNL and should be incorporated into current diagnostic criteria. Leukemia (2013) 27, 1870–1873; doi:10.1038/leu.2013.122 Keywords: myeloproliferative; G-CSF; severe congenital neutropenia; hereditary neutrophilia INTRODUCTION acquired extracellular domain mutations are infrequently reported 8,10 11 Colony-stimulating factor 3 receptor gene (CSF3R), mapping to in acute myeloid leukemia. Most recently, Maxson et al. made chromosome 1p34.3, encodes the trans-membrane receptor for the seminal observation regarding the association between CSF3R granulocyte colony-stimulating factor (G-CSF; CSF3), which pro- mutations and chronic neutrophilic leukemia (CNL). The current vides the proliferative and survival signal for granulocytes and also study was undertaken to determine the frequency, location and contributes to their differentiation and function.1 CSF3R harbors 17 specificity of CSF3R mutations in CNL and the closely related exons and its protein 813 amino acids. The cytoplasmic domain of atypical chronic myeloid leukemia (aCML). CSF3R is functionally assigned to proliferation (proximal region) and differentiation/regulation of proliferation (distal region).2 Nonsense somatic mutations affecting the cytoplasmic domain PATIENTS AND METHODS of CSF3R and leading to carboxyl-truncation have been described Patients and samples in B40% of patients with severe congenital neutropenia, where The current study was approved by the Mayo Clinic institutional review they are acquired and occur in conjunction with other inherited board. Patients were primarily identified through search of hematopathol- mutations (for example, ELANE and HAX1).3 Such mutations appear ogy databases for a diagnosis of ‘CNL’ or ‘aCML’. Inclusion to the current to be stem cell-derived,3 associated with but not essential for study required availability of archived bone marrow or peripheral blood severe congenital neutropenia -associated acute myeloid granulocytes for DNA extraction, as well as bone marrow morphology and 4,5 cytogenetic information at the time of first referral to the Mayo Clinic. The leukemia, promote STAT5-mediated clonal advantage in diagnoses of CNL, aCML, chronic myelomonocytic leukemia (CMML) and mouse progenitor cells6 and co-operate with other oncogenes 5,7 primary myelofibrosis (PMF) were confirmed by World Health Organization to induce acute myeloid leukemia. Severe congenital (WHO) criteria.12 CMML and PMF patients were selected from databases of neutropenia -associated CSF3R mutations occasionally affect the patients previously annotated for other mutations.13,14 Patient information extracellular domain of the receptor.4,8 was updated through review of patient histories and correspondence, A germline CSF3R mutation (C-to-A substitution at nucleotide social security death index or a telephone call to the patient or their local 2088; T617N) was recently described in autosomal dominant physician. hereditary neutrophilia associated with splenomegaly and 9 increased circulating CD34-positive myeloid progenitors; Mutation screening functional studies suggested enhanced receptor dimerization For CSF3R mutation analysis, exons 14–17 were amplified for all clinically and signaling that was abrogated by JAK2 inhibition and suspected cases of CNL or aCML using standard PCR conditions. Primers induction of neutrophilia and splenomegaly in mice.9 Similar but for CSF3R were as follows: 14 forward: 50-CCACGGAGGCAGCTTTAC-30, 1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA; 2Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA; 3Division of Cytogenetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA; 4Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR, USA; 5Knight Cancer Institute, Portland, OR, USA and 6Department of Cell and Development Biology, Oregon Health and Science University, Portland, OR, USA. Correspondence: Professor A Tefferi, Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA. E-mail: [email protected] Received 12 April 2013; accepted 16 April 2013; accepted article preview online 22 April 2013; advance online publication, 17 May 2013 CSF3R mutations in chronic neutrophilic leukemia A Pardanani et al 1871 14 reverse: 50-AAATCAGCATCCTTTGGGTG-30; 15 forward: 50-TGACTTTGAA distribution of continuous variables between categories were analyzed by TCCCCTGGTC-30, 15 reverse: 50-TGAGGTTCCCTGTGGGTG-30; 16 forward: either Mann–Whitney (for comparison of two groups) or Kruskal–Wallis 50-AAAATGGAAAGATCGGAGGG-30, 16 reverse: 50-CTTGGCTTCAGAAGG (comparison of three or more groups) test. Patient groups with nominal TGTCC-30, and 17 forward: 50-CTGTCACTTCCGGCAACAT-30, 17 reverse: variables were compared by w2 test. Overall survival was calculated from 50-TGGCCCAAAGACACAGTCGT-30. Following amplification, the PCR pro- the date of first referral to the date of death (uncensored) or last contact ducts were sequenced via standard capillary electrophoresis by Applied (censored). Survival curves were prepared by the Kaplan–Meier method Biosystems 3730 series DNA Analyzers (Carlsbad, CA, USA), and results and compared by the log-rank test. The Stat View (SAS Institute, Cary, NC, were analyzed using Sequencher software (Gene Codes Inc., Ann Arbor, MI, USA) statistical package was used for all calculations. USA). Patients with CMML and PMF were screened for exon 14 mutations only. PCR and Sanger sequencing was used for SETBP1 mutation screening in RESULTS PMF, CNL and aCML patients (forward primer 50-ATGCACCCACTTTCAA CACA-30 and reverse primer 50-AAAAGGCACCTTTGTCATGG-30 to generate CSF3R mutation screening included exons 14 through 17 for all 54 sequence for the amino-acid region 825–1013). For the CMML cohort, clinically suspected cases of ‘CNL’ (n ¼ 35) or ‘aCML (n ¼ 19). An we used the ViiA7 quantitative RT-PCR platform (qPCR) and MeltDoctor additional 170 patients with CMML (n ¼ 94) or PMF (n ¼ 76) were high-resolution melting assay (Life Technologies, Grand Island, NY, USA) screened for mutations involving CSF3R exon 14 only. In addition, using forward primer 50-GCGAGATTGGCTCCCTAAAG-30 and reverse primer SETBP1 mutation screening was performed in all the cases. All 0 0 5 -CCAGGGAGCAGAAATCAAAA-3 to generate sequence for the amino- study patients underwent bone marrow biopsy with cytogenetic acid region 860–1000. Targeted cases were validated using Sanger assessment and presence of BCR–ABL1 was excluded in every case sequencing to confirm the presence of a mutation. of suspected CNL by FISH and/or PCR analysis. Statistical analysis All statistical analyses considered clinical and laboratory parameters Confirmation of diagnosis according to WHO criteria obtained at the time of first referral, which coincided in most instances Central review of clinicopathological data for the 54 clinically with the time of bone marrow /granulocyte collection. Differences in the suspected cases of CNL or aCML, in order to identify those who Table 1. Mutational status and other clinical and laboratory characteristics of 27 patients with clinically suspected chronic neutrophilic leukemia Age Sex WHO- MGUS/ CSF3R SETBP1 JAK2 WBC PMN Immature Blast Monocyte defined lymphoma mutation (type) mutation mutation ( Â 109/l) (%) cells (%) (%) (%) 37 F Yes No T618I WT WT 72.8 94 3 0 1 78 M Yes No T618I G870D WT 29.4 78a 11a 00 55 M Yes No T618I WT WT 81.3 85 5 0 2 79 F Yes No T618I, WT WT 38.0 91 0 0 1 2341_2342insC 68 M Yes No T618I D868N WT 49.2 85 7 0 2 79 M Yes No T618I WT 84.7 93 4 0 2 73 M Yes No T618I G870D WT 58.7 82 0 0 10a 80 M Yes No T618I WT WT 21.7 90 0 0 1 47 M Yes No T618I G872R WT 22.6 87 5 0 1 63 F Yes No T618I WT WT 65.9 92 1 0 5 26 F Yes No I598I WT
Load more

Recommended publications
  • My Beloved Neutrophil Dr Boxer 2014 Neutropenia Family Conference
    The Beloved Neutrophil: Its Function in Health and Disease Stem Cell Multipotent Progenitor Myeloid Lymphoid CMP IL-3, SCF, GM-CSF CLP Committed Progenitor MEP GMP GM-CSF, IL-3, SCF EPO TPO G-CSF M-CSF IL-5 IL-3 SCF RBC Platelet Neutrophil Monocyte/ Basophil B-cells Macrophage Eosinophil T-Cells Mast cell NK cells Mature Cell Dendritic cells PRODUCTION AND KINETICS OF NEUTROPHILS CELLS % CELLS TIME Bone Marrow: Myeloblast 1 7 - 9 Mitotic Promyelocyte 4 Days Myelocyte 16 Maturation/ Metamyelocyte 22 3 – 7 Storage Band 30 Days Seg 21 Vascular: Peripheral Blood Seg 2 6 – 12 hours 3 Marginating Pool Apoptosis and ? Tissue clearance by 0 – 3 macrophages days PHAGOCYTOSIS 1. Mobilization 2. Chemotaxis 3. Recognition (Opsonization) 4. Ingestion 5. Degranulation 6. Peroxidation 7. Killing and Digestion 8. Net formation Adhesion: β 2 Integrins ▪ Heterodimer of a and b chain ▪ Tight adhesion, migration, ingestion, co- stimulation of other PMN responses LFA-1 Mac-1 (CR3) p150,95 a2b2 a CD11a CD11b CD11c CD11d b CD18 CD18 CD18 CD18 Cells All PMN, Dendritic Mac, mono, leukocytes mono/mac, PMN, T cell LGL Ligands ICAMs ICAM-1 C3bi, ICAM-3, C3bi other other Fibrinogen other GRANULOCYTE CHEMOATTRACTANTS Chemoattractants Source Activators Lipids PAF Neutrophils C5a, LPS, FMLP Endothelium LTB4 Neutrophils FMLP, C5a, LPS Chemokines (a) IL-8 Monocytes, endothelium LPS, IL-1, TNF, IL-3 other cells Gro a, b, g Monocytes, endothelium IL-1, TNF other cells NAP-2 Activated platelets Platelet activation Others FMLP Bacteria C5a Activation of complement Other Important Receptors on PMNs ñ Pattern recognition receptors – Detect microbes - Toll receptor family - Mannose receptor - bGlucan receptor – fungal cell walls ñ Cytokine receptors – enhance PMN function - G-CSF, GM-CSF - TNF Receptor ñ Opsonin receptors – trigger phagocytosis - FcgRI, II, III - Complement receptors – ñ Mac1/CR3 (CD11b/CD18) – C3bi ñ CR-1 – C3b, C4b, C3bi, C1q, Mannose binding protein From JG Hirsch, J Exp Med 116:827, 1962, with permission.
    [Show full text]
  • Hyperleukocytosis (Re)Visited- Is It Case Series Always Leukaemia: a Report of Two Pathology Section Cases and Review of Literature Short Communication
    Review Article Clinician’s corner Original Article Images in Medicine Experimental Research Miscellaneous Letter to Editor DOI: 10.7860/JCDR/2020/40556.13409 Case Report Postgraduate Education Hyperleukocytosis (Re)Visited- Is it Case Series always Leukaemia: A Report of Two Pathology Section Cases and Review of Literature Short Communication ASHUTOSH RATH1, RICHA GUPTA2 ABSTRACT Hyperleukocytosis is defined as total leukocyte count of more than 100×109/L. Commonly seen in leukaemic conditions, non- leukaemic causes are usually not encountered and thought of. We report two such non-malignant cases of hyperleukocytosis. A six-year old girl presented with fever, cough and respiratory distress with a leukocyte count of 125.97×109/L. Another case is of a two-month old female infant, who presented with fever and respiratory distress and a leukocyte count of 112.27×109/L. The present case thrives to highlight various possible causes of hyperleukocytosis with an emphasis on non-malignant causes. Also, important complications and management of hyperleukocytosis are discussed. Keywords: Benign, Leukocytosis, Leukostasis CASE REPORT 1 for methicillin-resistant Staphylococcus aureus and was started A six-year-old girl was admitted with complaints of fever, non- on intravenous Vancomycin along with supportive care. Serial productive cough for one week and severe respiratory distress for monitoring of TLC revealed a gradual reduction and it returned to the the past one day. There was no other significant history. On physical baseline of 15×109/L after eight days. The patient was discharged examination, the patient had mild pallor. Respiratory examination after 10 days of hospital stay.
    [Show full text]
  • Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency
    Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck.
    [Show full text]
  • Primary Immunodeficiency Disorders
    ALLERGY AND IMMUNOLOGY 00954543 /98 $8.00 + .OO PRIMARY IMMUNODEFICIENCY DISORDERS Robert J. Mamlok, MD Immunodeficiency is a common thought among both patients and physicians when confronted with what is perceived as an excessive num- ber, duration, or severity of infections. Because of this, the starting point for evaluating patients for suspected immunodeficiency is based on what constitutes ”too many infections.” It generally is agreed that children with normal immune systems may have an average of 6 to 8 respiratory tract infections per year for the first decade of life. Even after a pattern of ab- normal infection is established, questions of secondary immunodeficiency should first be raised. The relatively uncommon primary immunodefi- ciency diseases are statistically dwarfed by secondary causes of recurrent infection, such as malnutrition, respiratory allergy, chronic cardiovascular, pulmonary, and renal disease, and environmental factors. On the other hand, a dizzying spiral of progress in our understanding of the genetics and immunology of primary immunodeficiency disease has resulted in improved diagnostic and therapeutic tools. Twenty-five newly recognized immunologic disease genes have been cloned in the last 5 ~ears.2~It has become arguably more important than ever for us to recognize the clinical and laboratory features of these relatively uncommon, but increasingly treatable, disorders. CLASSIFICATION The immune system has been classically divided into four separate arms: The B-cell system responsible for antibody formation, the T-cell sys- From the Division of Pediatric Allergy and Immunology, Texas Tech University Health Sci- ences Center, Lubbock, Texas PRIMARY CARE VOLUME 25 NUMBER 4 DECEMBER 1998 739 740 MAMLOK tem responsible for immune cellular regulation, the phagocytic (poly- morphonuclear and mononuclear) system and the complement (opsonic) system.
    [Show full text]
  • Fracp Lecture 2010 Immune Deficiency 3
    FRACP LECTURE 2010 IMMUNE DEFICIENCY 3 DR MARNIE ROBINSON PAEDIATRIC IMMUNOLOGIST/ALLERGIST IMMUNOLOGY LECTURE 3 • Neutrophil defects • INTERFERON –Y /IL‐12 pathway defect • Dysregulatory immune dfiideficienc ies NEUTROPHIL DEFECTS • Neutropaenia – Allo immune /au to immune – Kostmann, WHIM – cyclllical • Chronic granulomatous disease • Leukocyte adhesion deficiency • Neutrophil specific granule deficiency • Chediak –higashi syndrome AUTOIMMUNE NEUTROPAENIA • Antibodies against different neutrophil antigen • Aeitiology unknown • Slightly more common in females • Present with skin and upper respiratory tract infections (pneumonia /menin gitis /se psis less common) • Neutrophil count usually <0. 5 but may increase during infection • Treatment with G‐CSF (IVIG) • Usually remits spontaneously by <24 months ALLOIMMUNE NEUTROPAENIA • Caused by transplacental transfer of maternal against the FcyRIIIb isotypes of NA 1 and NA2 causing immune destruction of neutrophils • Incidence of 1/500 • Usually presents in first weeks of life • Present with omphalitis, cellulitis, pneumonia • Diagnosed by detection of neutrophil specific alloantibodies in maternal blood • Treat with G‐CSF • resolves with waning of maternal antibodies KOSTMANN’S SYNDROME • Bone marrow granulocyte arrest at promyeolocyte or myelocyte stage • Present early in life (usually <6 months) • Present with omphalitis , respiratory tract ifinfect ions, skin and liver abscesses • Increased susceptibility to AML • Treatment is with G‐CSF CYCLICAL NEUTROPAENIA • Defect in elastase 2 • Sporadic
    [Show full text]
  • The Significance of Various Granulocytic Inclusions
    4/8/19 THE SIGNIFICANCE OF VARIOUS DISCLOSURES GRANULOCYTIC INCLUSIONS ¡ No relevant financial interests to disclose. KRISTLE HABERICHTER, DO, FCAP GRAND TRAVERSE PATHOLOGY, PLLC OBJECTIVES GRANULOCYTES ¡ Innate immune system ¡ Travel to sites of infection, recognize and phagocytose pathogens ¡ Recognize common and uncommon granulocytic inclusions, including those associated with certain ¡ Utilize numerous cytotoxic mechanisms to kill pathogens inherited disorders and infectious etiologies ¡ Granulopoiesis occurs in the bone marrow ¡ Sufficient stem cells, adequate microenvironment, and regulatory factors ¡ Identify newly described green neutrophilic inclusions ¡ Granulocyte colony stimulating factor (G-CSF) → Granulocytes ¡ Monocyte colony stimulating factor (M-CSF) → Monocytes ¡ Understand the clinical significance and implications of various inclusions ¡ Granulocyte-monocytes colony stimulating factor (GM-CSF) → Granulocytes & Monocytes ¡ 1-3 weeks for complete granulopoiesis to occur ¡ Neutrophils only circulate for a few hours before migrating to the tissues Photo by K. Haberichter (Giemsa, 1000x) GRANULOCYTES INCLUSION CATEGORIES ¡ Primary granules → Myeloperoxidase Reactive/Acquired Changes Congenital Abnormalities Infectious Etiologies ¡ “Late” myeloblasts and promyelocytes ¡ To x ic G r a n u la t io n ¡ Chédiak-Higashi Syndrome ¡ Anaplasma ¡ Secondary granules → Leukocyte alkaline phosphatase ¡ Döhle Bodies ¡ Alder-Reilly Anomaly ¡ Ehrlichia ¡ Myelocytes, metamyelocytes, band and segmented neutrophils ¡ Cytokine Effect ¡ May-Hegglin
    [Show full text]
  • Blood and Immunity
    Chapter Ten BLOOD AND IMMUNITY Chapter Contents 10 Pretest Clinical Aspects of Immunity Blood Chapter Review Immunity Case Studies Word Parts Pertaining to Blood and Immunity Crossword Puzzle Clinical Aspects of Blood Objectives After study of this chapter you should be able to: 1. Describe the composition of the blood plasma. 7. Identify and use roots pertaining to blood 2. Describe and give the functions of the three types of chemistry. blood cells. 8. List and describe the major disorders of the blood. 3. Label pictures of the blood cells. 9. List and describe the major disorders of the 4. Explain the basis of blood types. immune system. 5. Define immunity and list the possible sources of 10. Describe the major tests used to study blood. immunity. 11. Interpret abbreviations used in blood studies. 6. Identify and use roots and suffixes pertaining to the 12. Analyse several case studies involving the blood. blood and immunity. Pretest 1. The scientific name for red blood cells 5. Substances produced by immune cells that is . counteract microorganisms and other foreign 2. The scientific name for white blood cells materials are called . is . 6. A deficiency of hemoglobin results in the disorder 3. Platelets, or thrombocytes, are involved in called . 7. A neoplasm involving overgrowth of white blood 4. The white blood cells active in adaptive immunity cells is called . are the . 225 226 ♦ PART THREE / Body Systems Other 1% Proteins 8% Plasma 55% Water 91% Whole blood Leukocytes and platelets Formed 0.9% elements 45% Erythrocytes 10 99.1% Figure 10-1 Composition of whole blood.
    [Show full text]
  • Persistent Eosinophilia Is a Challenging Problem
    DOI: 10.26717/BJSTR.2017.01.000244 Nahla A M Hamed. Biomed J Sci & Tech Res ISSN: 2574-1241 Editorial Open Access Persistent Eosinophilia is a Challenging Problem Nahla AM Hamed* Professor of Hematology, Faculty of Medicine, Alexandria University, Egypt Received: July 25, 2017; Published: August 01, 2017 *Corresponding author: Nahla AM Hamed, Professor of Hematology, Faculty of Medicine, Alexandria University, Egypt Abstract 9 HE is defined as >1.5 x 10 /L eosinophils in the blood on 2 examinations (interval >1 mo) and/or tissue HE defined by: eosinophils percentage in BM section exceeding 20% of all nucleated cells; and/or extensive eosinophilic tissue infiltration by pathologist opinion; and/or presenceAbbreviations: of marked deposition of eosinophil granule proteins (in the absence or presence of major tissue eosinophils infiltration). AEC: absolute eosinophil count; HE: Hypereosinophilia; ABPA: Allergic Bronchopulmonary Aspergillosis; B-ALL: Acute B-cell lymphoblastic leukemia; GVHD: Graft-Versus-Host Disease; BM: Bone Marrow; PB: Peripheral Blood; IL5: Interleukin 5; AML: Acute Myeloid Leukemia; LV: Lymphocytic Variant; Th2:T-cells have a helper type 2; EPPER: Eosinophilic, polymorphic, and pruritic Eruption Associated with Radiotherapy; MPN: Myeloproliferative Neoplasm; HES: Hypereosinophilic Syndrome; PDGFRA: Platelet-Derived Growth Factor Receptor Alpha; PDGFRB: Platelet-Derived Growth Factor Receptor Beta; FGFR1: Fibroblast Growth Factor Receptor 1; CEL-NOS: Chronic Eosinophilic Leukemia-Not Otherwise Specified; MDS: Myelodysplastic Syndrome; IgH: Ig Heavy Chain; EBV: Epstein-Barr virus Introduction cystic structures (e.g. hydatid cyst, neurocysticercosis) are unlikely Eosinophilia3 is defined as an AEC >500/μL [1].3 The severity ), and severe to cause eosinophilia [7]. Disseminated coccidioidomycosis and of eosinophilia has3 been arbitrarily divided into mild9 (AEC: 500- aspergillosis (when presenting as ABPA) are well-known fungal 1,500/mm ), moderate (AEC: 1,500-5,000/mm causes of eosinophilia.
    [Show full text]
  • Canine Granulocytopathy Syndrome an Inherited Disorder Ofleukocyte Function
    Canine Granulocytopathy Syndrome An Inherited Disorder ofLeukocyte Function Harland W. Renshaw, DVM, PhD, and William C. Davis, PhD A disease closely resembling the human neutrophil dysfunction syndromes has been identified in a colony of dogs. The syndrome, referred to as the canine gran- ulocytopathy syndrome, is characterized by recurrent life-threatening bacterial infec- tions and a greatly shortened life span. The disease is genetically determined, being transmitted as an autosomal recessive trait. The increased susceptibility to pyogenic infections and shortened life span is related to an impairment of leukocvte function at the cellular level. Preparations of neutrophils from affected animals exhibit impaired in ritro killing of Escherichia coli. The defect in bactericidal activity is associated with reduced glucose oxidation by the hexose monophosphate shunt and an increased capac- ity to reduce nitroblue tetrazolium dye. The data obtained thus far indicate the canine granulocytopathy syndrome will be of considerable value as a model for the study of granulocytopathy syndromes in man. (Am J Pathol 95:731-744, 1979) STUDIES OF LEUKOCY-TE structure and function in host defense failure syndromes of man and animals have provided dramatic evidence for the necessitv of adequate neutrophil function for normal host resis- tance.`6 A group of human diseases, characterized clinically bv enhanced susceptibilitv to pyogenic infections, has been related to impaired killing of microorganisms by neutrophils and monocytes.7-12 A direct correlation
    [Show full text]
  • Eosinophilia and Neutrophilia Associated with Antipd-1 Use In
    ISSN: 2688-8203 DOI: 10.33552/ACRCI.2021.03.000555 Advances in Cancer Research & Clinical Imaging Case Report Copyright © All rights are reserved by Yasir Khan Eosinophilia and Neutrophilia Associated with Anti- PD-1 use in Metastatic Non-Small Cell Lung Cancer – A Case Report Yasir Khan* and Christopher Lomma Department of Medical Oncology, Fiona Stanley Hospital, Western Australia, Australia *Corresponding author: Yasir Khan, Department of Medical Oncology, Fiona Stanley Received Date: January 23, 2021 Hospital, Australia. Published Date: January 29, 2021 Abstract The use of immunotherapy has dramatically changed the way many cancers are treated with several studies having looked at the relationship between eosinophils and immunotherapy. This case study reports nivolumab induced eosinophilia and neutrophilia with no other systemic adverse effects in a patient with metastatic non-small cell lung cancer. A 61-year-old woman with Eastern Cooperative Oncology Group performance status 1 was diagnosed with metastatic non-small cell lung cancer without any driver mutations and was commenced on nivolumab after progressing on platinum doublet therapy. She had mild eosinophilia and neutrophilia at baseline in the context of a lower respiratory tract infection which peak levels at week-35. She developed postural hypotension during the course of her disease and prednisolone was commenced to treat possible became more pronounced with the introduction of nivolumab. Nivolumab was ceased at week-26 due to significant eosinophilia and reached for 8 months after commencement of immunotherapy before progression of disease leading to clinical deterioration and death. Asymptomatic adrenal insufficiency from metastasis. The introduction of steroids led to the improvement in eosinophilia and neutrophilia.
    [Show full text]
  • Neutrophilic Leukocytosis in Advanced Stage Polycythemia Vera
    Modern Pathology (2015) 28, 1448–1457 1448 © 2015 USCAP, Inc All rights reserved 0893-3952/15 $32.00 Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications Leonardo Boiocchi1,2, Umberto Gianelli2, Alessandra Iurlo3, Falko Fend4, Irina Bonzheim4, Daniele Cattaneo3, Daniel M Knowles1 and Attilio Orazi1 1Department of Pathology and Laboratory Medicine, Weill Cornell Medical College/New York Presbyterian Hospital, New York, NY, USA; 2Hematopathology Service, Division of Pathology, Department of Pathophysiology and Transplantation, University of Milan and IRCCS Ca’ Granda - Ospedale Maggiore Policlinico Foundation, Milan, Italy; 3Oncohematology Unit of the Elderly, Division of Oncohematology, IRCCS Ca’ Granda - Ospedale Maggiore Policlinico Foundation, Milan, Italy and 4Department of Pathology, University of Tubingen, Tubingen, Germany Polycythemia vera in 20–30% of cases progresses towards post-polycythemic myelofibrosis, an advanced phase characterized by decreased red blood cells counts and increasing splenomegaly with extramedullary hematopoiesis. There is evidence that the presence of neutrophilic leukocytosis at polycythemia vera disease outset is associated with an increased risk of recurrent thrombosis. However, its clinical significance when developing later in the course of the disease is not well defined. Over a period of 8 years we identified from the files of two reference centers 10 patients (7M/3F, median age: 68 years) who developed persistent absolute leukocytosis ≥ 13 × 109/l (median: 25.1 × 109/l; range: 16.1–89.7 × 109/l) at or around the time of diagnosis of post-polycythemic myelofibrosis (median interval from diagnosis:0 months; range: − 6/31) and persisted for a median period of 13 months. Peripheral blood smears showed numerous neutrophils without dysplastic features and, in four, ≥ 10% immature myeloid precursors.
    [Show full text]
  • Diagnosis and Management of Immunodeficiencies in Adults By
    GUIDELINES Diagnosis and Management of Immunodefi ciencies in Adults by Allergologists JM García,1 P Gamboa,2 A de la Calle,3 MD Hernández,4 MT Caballero,5 on behalf of the Committee of Immunology of the Spanish Society of Allergology and Clinical Immunology (SEAIC) (BE García, M Labrador, C Lahoz, N Longo Areso, M López Hoyos, J Martínez Quesada, L Mayorga, FJ Monteseirin, ML Sanz) 1Department of Pediatric Allergology and Clinical Immunology, Hospital de Cruces, Baracaldo-Vizcaya, Spain 2Department of Allergology, Hospital de Basurto, Bilbao, Spain 3Department of Allergology, Hospital Virgen Macarena, Sevilla, Spain 4Department of Allergology, Hospital La Fe, Valencia, Spain 5Department of Allergology, University Hospital La Paz, Madrid, Spain ■ Abstract Primary immunodefi ciencies (PIDs) are genetic diseases that cause alterations in the immune response and occur with an increased rate of infection, allergy, autoimmune disorders, and cancer. They affect adults and children, and the diagnostic delay, morbidity, effect on quality of life, and socioeconomic impact are important. Therapy (γ-globulin substitution in most cases) is highly effective. We examine adult PIDs and their clinical presentation and provide a sequential and directed framework for their diagnosis. Finally, we present a brief review of the most important adult PIDs, common variable immunodefi ciency, including diagnosis, pathogenesis, clinical signs, and disease management. Key words: Immunologic defi ciency syndromes. Common variable immunodefi ciency. Adult. Allergologist. ■ Resumen Las inmunodefi ciencias primarias (IDP) son enfermedades genéticas que ocasionan alteraciones en la respuesta inmunológica y que cursan con aumento de infecciones, alergia, autoinmunidad y cáncer. Afectan tanto a adultos como a niños, y el retraso diagnóstico, la morbilidad, la afectación de calidad de vida de los pacientes y el impacto socioeconómico que implican son considerables.
    [Show full text]